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Napsin A is an aspartic proteinase expressed in lung and kidney. We have reported that napsin A is expressed in type II pneumocytes
and in adenocarcinomas of the lung. The expression of napsin was examined in 118 lung tissues including 16 metastases by in situ
hybridisation. Napsin was expressed in the tumour cell compartment in 33 of 39 adenocarcinomas (84.6%), in two of 11 large cell
carcinomas and in one lung metastasis of a renal cell carcinoma. Expression of napsin was found to be associated with a high degree
of differentiation in adenocarcinoma. Immunohistochemistry was performed for three proteins currently used as markers for lung
adenocarcinoma:surfactant protein-A, surfactant protein-B and thyroid transcription factor-1. Thyroid transcription factor-1 showed
the same sensitivity (84.6%) as napsin for adenocarcinoma, whereas surfactant protein-A and surfactant protein-B showed lower
sensitivities. Among these markers, napsin showed the highest specificity (94.3%) for adenocarcinoma in nonsmall cell lung carcinoma.
We conclude that napsin is a promising marker for the diagnosis of primary lung adenocarcinoma.
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Lung cancer is the leading cause of cancer mortality in the world
and one of the top incidence of cancers in Europe and the US
(Black et al, 1997; Wingo et al, 1999). Lung cancer has a poor
prognosis and even for patients with operable disease, the 5-year
survival rate is 14% in the US (Landis et al, 1998). Nonsmall cell
lung cancer (NSCLC), essentially consisting of adenocarcinoma,
squamous cell carcinoma (epidermoid carcinoma) and large cell
carcinoma, accounts for approximately 80% of all lung cancers
(Travis et al, 1995). The incidence of pulmonary adenocarcinoma
has been increasing and adenocarcinoma is now the most common
histologic subtype in the US (Charloux et al, 1997; Landis et al,
1998).
The lung is also a common site for metastases from tumours
growing at other sites. From a clinical point of view, it is important
to distinguish between primary lung adenocarcinoma and meta-
static adenocarcinoma in the lung since treatment protocols differ
depending on the origin. Primary lung adenocarcinoma develops
from type II pneumocytes and from bronchiolar nonciliated
secretory cells (Clara cells). Surfactant apoproteins, including
surfactant protein-A (Sp-A) and surfactant protein-B (Sp-B) are
used as markers for lung adenocarcinoma and thyroid transcrip-
tion factor-1 (TTF-1) is used as a marker for lung adenocarcinoma,
large cell carcinoma, small cell carcinoma and thyroid carcinoma
(Kaufmann and Dietel, 2000b).
Recently, a new aspartic proteinase, napsin A, was cloned and
shown to be expressed in lung and kidney (Tatnell et al, 1998). Our
group and another group have shown that napsin A is identical to
the protein spots TAO1/TAO2 detected by two-dimensional gel
electrophoresis of lung adenocarcinoma, and that napsin A is
expressed in type II pneumocytes and lung adenocarcinomas
(Chuman et al, 1999; Hirano et al, 2000). However, the detailed
expression patterns of napsin A in association with other markers
in lung cancer remain to be clarified. In this study, we examined
napsin expression by in situ hybridisation and performed
immunohistochemistry for Sp-A, Sp-B and TTF-1 using 118 lung
tumour specimens to investigate the expression of napsin and
other markers in lung cancer.
MATERIALS AND METHODS
Tissues
One hundred and eighteen lung tumour tissues, from patients
treated in the Karolinska Hospital from 1994 to 1999, were selected
for this study. The samples included 39 adenocarcinomas
including seven bronchioloalveolar carcinomas (BAC), 11 large
cell carcinomas, 31 squamous cell carcinomas, 15 small cell
carcinomas, six carcinoids and 16 metastasised tumours in the
lung. The origins of the metastasised tumours included four
melanomas, one renal cell carcinoma, one gastric carcinoma, one
colon carcinoma, one salivary gland cancer, one prostate cancer,
one midline germ cell embryonic carcinoma, one basal cell
carcinoma and five sarcomas. The tissues were surgically resected
except small cell carcinoma and metastasised tumour tissues that
were obtained by biopsies. Forty-three were from female patients
and 75 were from male patients. The average age of the patients
was 62.4 years (range: 16–85). The study was approved by the local
institutional review board. The tumours were classified according
to the WHO histological typing of lung tumours (second edition).
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Formalin-fixed, paraffin-embedded tumour sections were depar-
affinised with xylene, treated with proteinase K (1mgml
 1,3 7 1C,
30min), transferred to 0.1 M triethanolamine buffer (5min) and
treated with triethanolamine containing 0.25% acetic anhydride for
10min. Sections were washed in 2 SSC, dehydrated and allowed
to air-dry. After overnight hybridisation (2 SSC, 50% formamide,
10% dextran sulphate, 551C) with an
35S-labelled RNA probe
(1.16 10
5c.p.m.ml
 1), sections were washed (the most stringent
step being 0.1 SSC, 15min at 601C) and treated with RNAse A
(20mgml
 1,3 7 1C, 30min). Finally, the slides were dehydrated, air-
dried, dipped in Kodak NTB emulsion, exposed for 6–21 days at
41C, developed and counter-stained with haematoxylin–eosin. The
probes were made using T3 (antisense) and T7 (sense) RNA
polymerase (Promega, Madison, WI) from a pCMS-EGFP vector
(BD Biosciences Clontech, Palo Alto, CA) containing an NheI/
EcoRI napsin A full-length cDNA. Both sense and antisense probes
were hybridised to all sections.
Immunohistochemistry
Formalin-fixed, paraffin-embedded lung tissues were subjected to
immunohistochemistry using an anti-Sp-A polyclonal antibody
(Chemicon International Inc., Tamacula, CA), an anti-Sp-B mono-
clonal antibody (personal gift from Dr Y Suzuki, Japan) and an anti-
TTF-1 monoclonal antibody (DAKO, Copenhagen, Denmark). The
sections were stained using the Ventana NexES Staining system
(Ventana Medical System, Tucson, AZ, USA). Briefly, 4-mms e c t i o n s
were incubated with the primary antibody for 30min at 371Ca n d
with a secondary biotinylated antibody for 10min.
The stained slides were analysed microscopically by three
observers in consensus and the results were expressed on a plus–
minus scale on the basis of the proportion of tumour cells stained:
0–10%,  ; 10–50%, +; 50–100%, ++. Only staining with apical
membranous or cytoplasmic staining pattern was accepted as
positive when stained with Sp-A/Sp-B. For TTF-1, only nuclear
staining pattern was accepted as positive although our series
contained a few tumours showing distinct specific cytoplasmic
staining pattern without background. The sensitivity of each
protein for primary adenocarcinoma and the specificity of each
protein for adenocarcinoma among NSCLC were calculated as
follows:
Sensitivity¼the number of adenocarcinomas expressing each
marker/the total number of adenocarcinomas (39),
Specificity¼the number of adenocarcinomas expressing each
marker/the number of NSCLC (adenocarcinoma, large cell
carcinoma and squamous cell carcinoma) expressing each marker.
RESULTS
Napsin expression was studied by in situ hybridisation in sections
containing normal lung tissues. Napsin expression was observed in
alveolar type II pneumocytes (Figure 1), but not in other types of
cells including bronchiolar epithelium and bronchial epithelium.
Hybridisation with a sense probe resulted in a diffuse background
and did not show any specific localisation (data not shown).
Expression of Sp-A, Sp-B and TTF-1 was examined by
immunohistochemistry. Staining was observed in alveolar type II
pneumocytes. Sp-A showed a membranous or cytoplasmic staining
pattern and Sp-B showed cytoplasmic staining, whereas TTF-1
showed a nuclear staining pattern (Figure 1). All four markers were
expressed in reactive type II pneumocyte hyperplasia lesions (data
not shown).
Napsin expression was examined in 118 lung tumour tissues.
Only expression by tumour cells was considered. Thirty-three
of 39 adenocarcinomas (84.6%) expressed napsin mRNA (Figure 2)
and two of 11 large cell carcinomas showed napsin mRNA
expression (Table 1). One lung metastasis of renal cell carcinoma
origin expressed napsin mRNA, consistent with the previously
described expression of napsin A in epithelial cells of renal tubules
Figure 1 Expression of napsin, Sp-A, Sp-B and TTF-1 in type II pneumocytes.
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tumours expressed napsin mRNA.
Sp-A, Sp-B and TTF-1 were expressed in adenocarcinomas
(Figure 2) but the expression was also observed in other types of
lung tumours (Table 1). In particular, TTF-1 expression was
observed in a large proportion (80%) of small cell carcinomas, in
agreement with previous reports (Fabbro et al, 1996; Kaufmann
and Dietel, 2000a). The sensitivity and specificity of each marker
for the diagnosis of adenocarcinoma among NSCLC were
calculated. Napsin and TTF-1 showed the highest sensitivity
(84.6%), and napsin had the highest specificity (94.3%). Two
adenocarcinomas were positive for napsin but negative for TTF-1.
Combining napsin and TTF-1 resulted in a higher sensitivity for
adenocarcinoma (89.7% (35 out of 39)) whereas the specificity was
the same as TTF-1 alone (76.7%).
The association between the expression of each marker and
differentiation grade of the adenocarcinoma is presented in
Figure 3. Expression of napsin and Sp-A were associated with a
high degree of tumour differentiation.
DISCUSSION
Napsin is found in two isoforms, napsin A and B, with highly
homologous nucleotide sequences (91.2%) (Tatnell et al, 1998).
Napsin A appears to be a functional proteinase, predominantly
expressed in lung and kidney. Napsin B is transcribed exclusively
in cells related to the immune system and lacks an in-frame stop
codon and is believed to be a pseudogene (Tatnell et al, 1998). In
the present study, napsin expression was examined by in situ
hybridisation of tissue sections. Expression was specifically assessed
Figure 2 Expression of napsin, Sp-A, Sp-B and TTF-1 in lung adenocarcinoma.
Table 1 Expression of markers in lung tumours
Napsin Sp-A Sp-B TTF-1 Total
Adenocarcinoma 33 24 24 33 39
Large cell carcinoma 2 3 1 6 11
Squamous cell carcinoma 0 4 5 4 31
Small cell carcinoma 0 0 1 12 15
Carcinoid 0 0 0 3 6
Metastatic tumour
a 1
(renal cell
carcinoma)
1
(salivary gland)
2
(salivary gland,
midline germ cell
embr. carcinoma)
01 6
Sensitivity
b (%) 84.6 61.5 61.5 84.6
Specificity
b (%) 94.3 77.4 80.0 76.7
aBrackets show the origins of metastatic tumours.
bSensitivity and specificity for adenocarcinoma among nonsmall cell lung cancer (adenocarcinoma, large cell carcinoma and
squamous cell carcinoma).
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tissue. Hybridisation signals from other cell types (e.g. lympho-
cytes) were not considered to avoid possible scoring of napsin B
expression.
We demonstrated napsin expression in type II pneumocytes,
which are identified by approximately cuboid shape, large and
roundish nucleus and cytoplasmic staining for Sp-A (Ten Have-
Opbroek et al, 1997). Type II pneumocytes are thought to be
progenitor cells of normal and neoplastic epithelial cells during the
repair of injury and during carcinogenesis (Adamson and Bowden,
1974; Mizutani et al, 1988; Linnoila et al, 1992). Napsin mRNA
was expressed in not only normal type II pneumocytes, but also
reactive type II pneumocyte hyperplasia and adenocarcinoma,
suggesting that napsin may be used as a novel type II lineage
marker.
Three different markers, Sp-A, Sp-B and TTF-1, are currently
used for the differential diagnosis of primary lung adenocarcino-
ma. TTF-1 appears to be the most sensitive of these markers
(Kaufmann and Dietel, 2000b). In agreement with that study, we
found a higher sensitivity of TTF-1 compared to Sp-A and Sp-B.
Napsin showed the same sensitivity as TTF-1. However, the
specificity of napsin to adenocarcinoma was the highest among the
markers examined. Napsin mRNA was expressed in primary lung
adenocarcinomas and in some large cell carcinomas, but not in
other types of primary lung cancers. This is in distinction from
TTF-1, which is also expressed in a large proportion of small cell
carcinomas (Table 1) (Fabbro et al, 1996; Kaufmann and Dietel,
2000a). Napsin expression was examined in a restricted number of
lung metastases. Expression was observed in one metastatic
tumour, from a renal cell carcinoma. This observation is consistent
with previous findings of napsin expression in renal tubules
(Schauer-Vukasinovic et al, 1999). Clearly, however, a large
number of metastases from different primary tumours have to
be examined before a firm conclusion as to the value of napsin as a
marker for the differential diagnosis between primary and
metastatic lung carcinoma can be made. The restricted tissue
distribution of napsin suggests that this proteinase may be a useful
marker.
Some aspartic proteinases are involved in cancer progression.
Overexpression of cathepsin D in transformed cells increases a
metastatic potential in mice (Garcia et al, 1990). High cytosolic
cathepsin D levels are associated with poor prognosis in primary
breast cancer (Foekens et al, 1999). Although we did not find an
association between napsin expression and patients’ prognosis in
this study (data not shown), a correlation between napsin
expression and the differentiation grade of adenocarcinoma was
observed in accordance with previous reports (Hirano et al, 1997,
2000). The high positive rate (more than 80%) of napsin in lung
adenocarcinoma and its close association with the differentiation
grade may suggest a role of napsin in cancer development or
differentiation.
In conclusion, we showed that napsin was expressed in a large
proportion of primary lung adenocarcinoma and showed its
association with the differentiation grade. The results suggest that
napsin is a promising marker for differential diagnosis of
adenocarcinoma in the lung.
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